Search 

Cor-Act Advanced Technologies, developing a life supporting system, for patients dying from chronic heart failure). Cor-Act will shortly launch the first fully implantable, Cardiac Assist Device with no blood contact. Our solution is designed as a cost- effective technology to solve the growing gap between of patients waiting for a transplant / mechanical support and the actual expensive available therapies. The Cor-Act’s Cardiac Assist Device system incorporates a miniaturized implantable pump connected to silicone elements which are pressing the myocardium.

CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications

immuno-oncology

inflammatory diseases

inflammatory autoimmune 

big data

biomarker

Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.

The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.  

CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials.